{
  "id": 10218947,
  "title": "Personalis CEO Christopher Hall sells $120,984 in company stock",
  "url": "https://urgent.news/2026/09/27/personalis-ceo-christopher-hall-sells-120-984-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-27T12:46:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/personalis-ceo-christopher-hall-sells-120984-in-company-stock-93CH-4918998"
  },
  "original_language": "en",
  "account": "Personalis CEO Christopher Hall disposed of 7,459 shares of the company's stock on September 18, 2026, selling them at $16.22 per share for a total of $120,984. This sale was to satisfy tax withholding requirements from the settlement of vested restricted stock units. Since the transaction, Hall now directly owns 228,527 shares of Personalis common stock. The stock's current price is $16.46, near its 52-week high of $18.89, leading an InvestingPro analysis to deem it overvalued. Investors can receive further insights through InvestingPro's ProTips and metrics. In a separate development, Tempus AI intends to acquire Personalis in a $1.5 billion deal, excluding Tempus AI's existing stake. This all-stock transaction will grant Personalis shareholders $16.25 per share, marking a 6% increase from the most recent closing price. Needham has kept its Buy rating on Tempus AI at $75.00, while downgrading Personalis to Hold at $75.00, citing the acquisition. The deal is expected to finalize in late 2026 or early 2027. Meanwhile, Needham lifted its price target for Personalis to $17, anticipating potential acquisition interest from firms like Merck & Co. On a positive note, Personalis received UK regulatory approval for its NeXT Personal Dx test, facilitating clinical trials across the UK.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Repligen CEO Olivier Loeillot sells $976,680 in company stock",
        "url": "https://urgent.news/2026/09/27/repligen-ceo-olivier-loeillot-sells-976-680-in-company-stock",
        "published": "2026-09-27T12:16:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}